Impact on the quality of life of the treatment of adductor spasmodic dysphonia with botulinum toxin A

Impacto en la calidad de vida del tratamiento de disfonía espasmódica aductora con toxina botulínica A

Published 2021-12-18

Open | Download
PDF Icon Flip Icon XML Icon
Issue
Vol. 3 No. 2 (2021)
Section
Research Article
How to Cite
1.
Impact on the quality of life of the treatment of adductor spasmodic dysphonia with botulinum toxin A. Rev. Investig. Innov. Cienc. Salud [Internet]. 2021 Dec. 18 [cited 2024 Nov. 15];3(2):24-3. Available from: https://riics.info/index.php/RCMC/article/view/66
DOI

https://doi.org/10.46634/riics.66
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Carolina Oliva Guerrero
Hospital Clínico Universidad de Chile; Santiago; Chile.
    https://orcid.org/0000-0003-2202-1948
    Luis Barahona Acevedo
    Hospital Clínico Universidad de Chile; Santiago; Chile.
      https://orcid.org/0000-0003-4293-9000
      Javiera Castro Arenas
      Universidad de Chile; Santiago; Chile.
        https://orcid.org/0000-0001-9792-1751
        Christian Olavarría Leiva
        Hospital Clínico Universidad de Chile; Santiago; Chile.
          https://orcid.org/0000-0001-8520-0164
          Show authors biography

          Introduction. Laryngeal dystonia or spasmodic dysphonia is characterized by involuntary contractions of internal laryngeal muscles that are triggered when speaking, being the adductor form the most frequent. Botulinum toxin injection is the management of choice. There are several validated instruments to assess response to therapy, one of them is the Voice Handicap Index-10 (VHI-10) questionnaire. The objective of this study is to characterize patients with adductor spasmodic dysphonia and evaluate the impact of the toxin on their quality of life.

          Method. A descriptive retrospective study was carried out in adult patients with a diagnosis of adductor spasmodic dysphonia treated with botulinum toxin A, between 2013-2021 at the Hospital Clínico Universidad de Chile. The epidemiological data of the patients and the VHI-10 survey were obtained before and after one month of each toxin injection was requested.

          Results. 55 patients (218 procedures) were included. The average dose used was 9.18 IU with an average interval of 7.4 months. The average VHI-10 score in the initial evaluation was 29.4 and post-infiltration was 14.96, being this difference significant (p <0.000001). In our series, almost a third had an associated neurological pathology, and 3.67% of mild and transitory complications were reported.

          Conclusion. Adductor spasmodic dysphonia has a great impact on the quality of life of patients, which is significantly reduced by injecting botulinum toxin A, a procedure that has been shown to be safe and effective.

          Article visits 679 | PDF visits 390

          1. Whurr R, Lorch M. Review of differential diagnosis and management of spasmodic dysphonia. Curr Opin Otolaryngol Head Neck Surg. 2016;24(3):203-207. Doi: https://doi.org/10.1097/MOO.0000000000000253
          2. Lorch MP, Whurr R. Tracing Spasmodic Dysphonia: The Source of Ludwig Traubes Priority. Ann Otol Rhinol Laryngol. 2016;125(8):672-676. Doi: https://doi.org/10.1177/0003489416646115
          3. Mor N, Simonyan K, Blitzer A. Central voice production and pathophysiology of spasmodic dysphonia. Laryngoscope. 2018;128(1):177-183. Doi: https://doi.org/10.1002/lary.26655
          4. Simonyan K, Ludlow CL. Abnormal structure-function relationship in spasmodic dysphonia. Cereb Cortex. 2012;22(2):417-425. Doi: https://doi.org/10.1093/cercor/bhr120
          5. Chen M, Summers RLS, Prudente CN, et al. Transcranial magnetic stimulation and functional magnet resonance imaging evaluation of adductor spasmodic dysphonia during phonation. Brain Stimul. 2020;13(3):908-915. Doi: https://doi.org/10.1016/j.brs.2020.03.003
          6. Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG. Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors. Otolaryngol - Head Neck Surg (United States). 2017;157(4):551-557. Doi: https://doi.org/10.1177/0194599817728521
          7. Ludlow CL, Domangue R, Sharma D, et al. Consensus-based attributes for identifying patients with spasmodic dysphonia and other voice disorders. JAMA Otolaryngol - Head Neck Surg. 2018;144(8):657-665. Doi: https://doi.org/10.1001/jamaoto.2018.0644
          8. Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG. Spasmodic Dysphonia: A Review. Part 2: Characterization of Pathophysiology. Otolaryngol - Head Neck Surg (United States). 2017;157(4):558-564. Doi: https://doi.org/10.1177/0194599817728465
          9. Brunetto B, Nazar R, Olavarría C, Gutiérrez A, del Peso G, Miranda M, Painepán JC. Experiencia con toxina botulínica en el tratamiento de la disfonía espasmódica. Rev. Otorrinolaringol. Cir. Cabeza y cuello. 2014, vol. 64, p. 105-112. Url: https://n9.cl/riics
          10. Faham M, Ahmadi A, Silverman E, Harouni GG, Dabirmoghaddam P. Quality of life after botulinum toxin injection in patients with adductor spasmodic dysphonia; a systematic review and meta-analysis. Journal of Voice. 2021 Mar 1;35(2):271-83. Doi: https://doi.org/10.1016/j.jvoice.2019.07.025
          11. Faham M, Torabinezhad F, Murry T, et al. Quality of life and voice changes after a single injection in patients with ADSD over time. J Voice 2019 Sep;33(5):721-727. Doi: https://doi.org/10.1016/j.jvoice.2018.04.023
          12. Rosen C, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the Voice Handicap Index-10. Laryngoscope. 2004;114:1549–1556. Doi: https://doi.org/10.1097/00005537-200409000-00009
          13. Núñez-Batalla F, Corte-Santos P, Señaris-González B, Llorente-Pendás JL, Gorriz-Gil C, Suarez-Nieto C. Adaptación y validación del índice de incapacidad vocal (VHI-30) y su versión abreviada (VHI-10) al español. Acta Otorrinolaringológica Española. 2007 Nov 1;58(9):386-92. Doi: https://doi.org/10.1016/S0001-6519(07)74954-3
          14. Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. European Journal of Neurology. 2010 Jul;17:28-30. Doi: https://doi.org/10.1111/j.1468-1331.2010.03047.x
          15. Patel AB, Bansberg SF, Adler CH, Lott DG, Crujido L. The Mayo Clinic Arizona spasmodic dysphonia experience: a demographic analysis of 718 patients. Annals of Otology, Rhinology & Laryngology. 2015 Nov;124(11):859-63. Doi: https://doi.org/10.1177/0003489415588557
          16. Paddle P, Husain I, Moniz C, Turner S, Franco Jr RA. Long-term dose stability of onabotulinumtoxinA injection for adductor spasmodic dysphonia: a 19-year single institution experience. Frontiers in surgery. 2017 Nov 29;4:70. Doi: https://doi.org/10.3389/fsurg.2017.00070. eCollection 2017
          17. French G, Bosch JD, Randall DR. Retrospective review of dosing trends in botulinum toxin injections for the treatment of adductor spasmodic dysphonia in a long-term cohort. Journal of Otolaryngology-Head & Neck Surgery. 2020 Dec;49(1):1-4. Doi: https://doi.org/10.1186/s40463-020-0401-4
          18. Blitzer A, Brin MF, Simonyan K, Ozelius LJ, Frucht SJ. Phenomenology, genetics, and CNS network abnormalities in laryngeal dystonia: A 30‐year experience. The Laryngoscope. 2018 Jan;128:S1-9. Doi: https://doi.org/10.1002/lary.27003
          19. Ozgursoy SK, Vargas ER, Heckman MG, Rutt AL. Demographics and coexisting tremor, cervical dystonia and vocal fold disorders in a group of patients with spasmodic dysphonia. Acta Otorhinolaryngologica Italica. 2020 Jun;40(3):198. doi: https://doi.org/10.14639/0392-100X-N0284
          20. Marchese MR, D'Alatri L, Bentivoglio AR, Paludetti G. OnabotulinumtoxinA for adductor spasmodic dysphonia (ADSD): functional results and the role of dosage. Toxicon. 2018 Dec 1;155:38-42. Doi: https://doi.org/10.1016/j.toxicon.2018.10.006
          21. Shoffel‐Havakuk H, Rosow DE, Lava CX, Hapner ER, Johns III MM. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: a national survey. The Laryngoscope. 2019 Jul;129(7):1650-6. Doi: https://doi.org/10.1002/lary.27696
          22. Young DL, Halstead LA. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues. Journal of Voice. 2014 Sep 1;28(5):614-7.) doi: https://doi.org/10.1016/j.jvoice.2013.10.024
          23. Bradley JP, Barrow EM, Hapner ER, Klein AM, Johns III MM. Botulinum toxin-a dosing trends for adductor spasmodic dysphonia at a single institution over 10 years. Journal of Voice. 2017 May 1;31(3):363-5. Doi: https://doi.org/10.1016/j.jvoice.2016.09.022
          24. McGarey Jr PO, Simpson CB, Daniero JJ. Practice Patterns and Barriers in Botulinum Toxin Injection for the Treatment of Voice Disorders. Journal of Voice. 2020 May 26;S0892-1997(20)30155-7. Doi: https://doi.org/10.1016/j.jvoice.2020.04.021
          25. Gilbert MR, Young VN, Smith LJ, Rosen CA. Multidose botulinum toxin A for intralaryngeal injection: a cost analysis. Journal of Voice. 2019 Mar 1;33(2):159-61. Doi: https://doi.org/10.1016/j.jvoice.2017.11.004
          26. Jacobson BH, Johnson A, Grywalski C, et al. The voice handicap index (VHI): development and validation. Am J Speech-Lang Pathol. 1997;6:66–70. Doi: https://doi.org/10.1044/1058-0360.0603.66
          27. Morzaria S, Damrose EJ. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia. Journal of Voice. 2012 May 1;26(3):378-80. Doi: https://doi.org/10.1016/j.jvoice.2010.07.011
          28. Neumann KJ, Dejonckere PH. Voice related quality of life in spasmodic dysphonia: a detailed VHI-analysis before and after botulinum treatment. InMAVEBA 2009 Dec 14 (p. 65). Url: https://n9.cl/psg5qb
          29. Novakovic D, Waters HH, D'Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. The Laryngoscope. 2011 Mar;121(3):606-12. Doi: https://doi.org/10.1002/lary.21395
          30. Yiu Y, Baylor CR, Bamer AM, Shelly S, Klein AM, Garrett CG, Pitman MJ. Validation of the Communicative Participation Item Bank as an Outcome Measure for Spasmodic Dysphonia. The Laryngoscope. 2021 Apr;131(4):859-64. Doi: https://doi.org/10.1002/lary.28897
          31. Aguayo AM, Corrales MT, Castro GF. Índice de discapacidad vocal pre-y postaplicación de toxina botulínica en pacientes con disfonía espasmódica. Anales Médicos de la Asociación Médica del Centro Médico ABC. 2017 Jun 15;62(2):100-5. Url: https://n9.cl/7psxo
          32. Dharia I, Bielamowicz S. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia in a large cohort. The Laryngoscope. 2020 Nov;130(11):2659-62. Doi: https://doi.org/10.1002/lary.28457
          Publish with RIICS

          Scimago

          Most read in the last 30 days

          Sistema OJS 3.4.0.7 - Metabiblioteca |